Drug Profile
CDX 014
Alternative Names: CDX-014; CR 014-vcMMAELatest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Amgen; CuraGen Corporation
- Developer Celldex Therapeutics Inc
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Membrane protein inhibitors; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ovarian cancer; Renal cell carcinoma